Predicting immunotherapy benefit in leiomyosarcoma through active chromatin cfDNA profiling.

Saved in:
Bibliographic Details
Title: Predicting immunotherapy benefit in leiomyosarcoma through active chromatin cfDNA profiling.
Authors: Lopes CDH; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Sinai Health System, University Health Network, Toronto, ON, Canada., Wu HT; Aqtual, Hayward, CA, USA., Dilger K; Aqtual, Hayward, CA, USA., Zhang YW; Aqtual, Hayward, CA, USA., Salawu A; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Sinai Health System, University Health Network, Toronto, ON, Canada., Stayner LA; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Gupta AA; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Hansen AR; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Spreafico A; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Bedard PL; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Louie MC; Aqtual, Hayward, CA, USA., Siu LL; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Princess Margaret Cancer Consortium, Marathon of Hope Cancer Centres Network, Toronto, ON, Canada., Abdul Razak AR; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. albiruni.razak@uhn.ca.; Sinai Health System, University Health Network, Toronto, ON, Canada. albiruni.razak@uhn.ca.
Source: NPJ precision oncology [NPJ Precis Oncol] 2026 May 05. Date of Electronic Publication: 2026 May 05.
Publication Type: Journal Article
Journal Info: Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol
Database: MEDLINE Ultimate
Description
ISSN:2397-768X
DOI:10.1038/s41698-026-01451-9